Common Contracts
2 similar Transition Services Agreement contracts by Idenix Pharmaceuticals Inc
EX-10.2 3 b67163ipexv10w2.htm EX-10.2 TRANSACTION SERVICES AGREEMENTTransition Services Agreement • May 5th, 2020
TRANSITION SERVICES AGREEMENT This Transition Services Agreement (“Transition Agreement”) is made as of 28 September 2007 between Idenix Pharmaceuticals, Inc. of 60 Hampshire Street, Cambridge, Massachusetts 02139, USA (“Idenix U.S.”), Idenix (Cayman) Limited c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (“Idenix Cayman” and, together with Idenix U.S., “Idenix”), and Novartis Pharma AG of Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”). INTRODUCTION Novartis and Idenix are parties to the Development, License and Commercialization Agreement made as of May 8, 2003, as amended by Amendment No. 1 dated as of April 30, 2004, Amendment No. 2 dated as of December 21, 2004, Amendment No. 3 dated as of February 27, 2006, and Amendment No. 4 dated as of even date as this Transition Agreement (as amended and updated, the “DLC Agreement”). Under Amendment No. 4 to the DLC Agreement (“Amendment No. 4”), Novartis and Idenix revised certa
TRANSITION SERVICES AGREEMENT IDENIX PHARMACEUTICALS, INC., IDENIX (CAYMAN) LIMITED NOVARTIS PHARMA AGTransition Services Agreement • November 8th, 2007 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This Transition Services Agreement (“Transition Agreement”) is made as of 28 September 2007 between Idenix Pharmaceuticals, Inc. of 60 Hampshire Street, Cambridge, Massachusetts 02139, USA (“Idenix U.S.”), Idenix (Cayman) Limited c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (“Idenix Cayman” and, together with Idenix U.S., “Idenix”), and Novartis Pharma AG of Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”).
